Skip to main content

MYM Closes Fifth Tranche of Non-Brokered Private Placement and Issues Shares Associated with Receiving Cultivation License

Tickers: XCNQ:MYM, XOTC:MYMMF
Tags: #MedicinalMarijuana



VANCOUVER, British Columbia - TheNewswire - February 13, 2020 - MYM Nutraceuticals Inc., (CNSX:MYM.CN) (OTC:MYMMF) ("MYM" or the "Company") announces it has closed the fifth tranche of the non-brokered private placement previously announced on January 14, 2020. The fifth tranche issued 2,327,142 units at a price of $0.06 per unit for gross proceeds of $139,628.52. There were no finders' fees payable on this tranche.

Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of $0.10 for a period of three years from the issue date. The warrants are subject to an acceleration provision that allows the Company to give notice of an earlier expiry date if the Company's weighted average share price on the CSE (or such other stock exchange the Company may be trading on) is equal or greater than $0.20 for a period of 10 consecutive trading days.

The offering was priced in the context of the market based on a price reservation made by the Company with the Canadian Securities Exchange ("CSE"). The private placement is subject to the approval of the CSE and the securities will be subject to a four-month hold period under securities laws. The Company intends to use the net proceeds from the private placement for working capital purposes.

Further to the Company's news releases dated February 1, 2017, May 4, 2018 and January 31, 2020, the Company announces that it has issued an aggregate of 952,000 common shares of the Company ("Shares") at a deemed price of $0.09 per Share in connection with the Company's subsidiary, Sublime Culture Inc., receiving its cultivation license (the "License") from Health Canada to produce at its indoor facility located in Laval, Quebec. The Shares were issued pursuant to certain agreements that provide for contingent payments through the issuance of Shares upon Sublime receiving the License.

All Shares issued in connection with the License are subject to a minimum four-month hold period as required by Canadian securities laws and the issuance of such Shares is subject to approval of the Canadian Securities Exchange (the "CSE").

About MYM Nutraceuticals Inc.

MYM is a licensed cannabis producer in Canada. We are uniquely positioned to opportunistically acquire and/or invest in companies within the cannabis and hemp industries that are in need of capital and management support. Our senior management team is made up of experts engaged in a wide array of disciplines - upper level management of public companies, finance, law, master growing, plant pathology, agricultural economics, pharmaceutical, engineering, global marketing, product development and branding, distribution and seed genetics. MYM is a shareholder in two production projects in Quebec and is actively looking to acquire complementary businesses and assets in the cannabis sector. MYM shares trade in Canada, Germany and the United States under the following symbols: (CSE: MYM) (OTC: MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

ON BEHALF OF THE BOARD

Howard Steinberg, CEO

MYM Nutraceuticals Inc.

www.mym.ca

Investor Relations

investors@mym.ca

Keep up to date with MYM on our social media channels:

Twitter: @mymnutra

Facebook: @mymnutra

Instagram: @mymnutra

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. The Company disclaims and does not undertake any intention or obligation to revise or update such statements, except as required by applicable law. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis dated October 28,, 2019 (the "MD&A") and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

Forward-looking statements may include, without limitation, statements relating to the Company's ability to acquire complementary businesses and assets in the cannabis and hemp industry or cannabis sector or to produce at its indoor facility.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

Copyright (c) 2020 TheNewswire - All rights reserved.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.